For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Analysts at Evercore ISI previously forecast that Vyalev could be one of AbbVie’s “biggest new product launches over the next year or two,” projecting the product could generate more than $2 ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

The creation of AbbVie In 2011 ... rather than being in hospital. The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025.

In the last three months, 11 analysts have published ratings on AbbVie ABBV ... The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie (NYSE:ABBV) will report third-quarter results next week and I expect to see a continuation of trends from the first half of the year with top and bottom-line beats and an improved full-year ...